药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2014年
6期
566-568
,共3页
抗肿瘤抗生素%南京市样本医院%用药分析%DDDs%DDC
抗腫瘤抗生素%南京市樣本醫院%用藥分析%DDDs%DDC
항종류항생소%남경시양본의원%용약분석%DDDs%DDC
Anticancer antibiotics%Sample hospitals of Nanjing%Medication analysis%Sales amount%DDDs%DDC
目的:评价南京地区27家样本医院2011~2013年抗肿瘤抗生素使用情况及特点,了解抗肿瘤抗生素治疗新理念和应用新药的新途径。方法:用限定日剂量法(DDDs)分析2011~2013年样本医院抗肿瘤抗生素应用的品种、数量、金额、日均用量数(DDDs)及日均费用(DDC)等情况。结果:抗肿瘤抗生素销售金额及销量逐年上升,最常用的是蒽环类抗肿瘤抗生素,已成为抗肿瘤抗生素的主体,销售金额排名前几位的药物主要是表柔比星、伊达比星、吡柔比星和阿霉素;DDDs排名前几位的药物主要是表柔比星、吡柔比星、丝裂霉素和阿霉素。大多数抗肿瘤抗生素的销量与使用同步性良好。结论:抗肿瘤抗生素的需求量逐年增加,尤其是蒽环类药物成为抗肿瘤抗生素的主流药物。
目的:評價南京地區27傢樣本醫院2011~2013年抗腫瘤抗生素使用情況及特點,瞭解抗腫瘤抗生素治療新理唸和應用新藥的新途徑。方法:用限定日劑量法(DDDs)分析2011~2013年樣本醫院抗腫瘤抗生素應用的品種、數量、金額、日均用量數(DDDs)及日均費用(DDC)等情況。結果:抗腫瘤抗生素銷售金額及銷量逐年上升,最常用的是蒽環類抗腫瘤抗生素,已成為抗腫瘤抗生素的主體,銷售金額排名前幾位的藥物主要是錶柔比星、伊達比星、吡柔比星和阿黴素;DDDs排名前幾位的藥物主要是錶柔比星、吡柔比星、絲裂黴素和阿黴素。大多數抗腫瘤抗生素的銷量與使用同步性良好。結論:抗腫瘤抗生素的需求量逐年增加,尤其是蒽環類藥物成為抗腫瘤抗生素的主流藥物。
목적:평개남경지구27가양본의원2011~2013년항종류항생소사용정황급특점,료해항종류항생소치료신이념화응용신약적신도경。방법:용한정일제량법(DDDs)분석2011~2013년양본의원항종류항생소응용적품충、수량、금액、일균용량수(DDDs)급일균비용(DDC)등정황。결과:항종류항생소소수금액급소량축년상승,최상용적시은배류항종류항생소,이성위항종류항생소적주체,소수금액배명전궤위적약물주요시표유비성、이체비성、필유비성화아매소;DDDs배명전궤위적약물주요시표유비성、필유비성、사렬매소화아매소。대다수항종류항생소적소량여사용동보성량호。결론:항종류항생소적수구량축년증가,우기시은배류약물성위항종류항생소적주류약물。
Objective: To comprehend the new therapeutic idea and way of using new drugs by estimating the using situation of anticancer antibiotics from 2011 to 2013 in 27 sample hospitals of Nanjing. Methods: With the method of defined daily dose (DDDs), the use of anticancer antibiotics was analyzed in respect of drug categories, consumption quantity, sales amount, DDDs and defined daily consumption (DDC), etc., from 2011 to 2013 in 27 sample hospitals. Results: The sales amount of anticancer antibiotics increased year by year, and the most commonly used drugs were antharcycline. The top four sales amounts were pharmorubicin, idarubicin, pirarubicin and adriamycin, the top four DDDs were pharmorubicin, pirarubicin, mitomycin and adriamycin. Most of the anticancer antibiotics sales amounts and the DDDs were concordant. Conclusion: The demand of anticancer antibiotics increased year by year. They have broad development prospects, especially antharcycline will become the leading anticancer antibiotics..